Dr. Tommy Rhee's Research Accepted for Presentation at the 2026 ASIPP Annual Meeting
Tampa, FL - Dr. Tommy Rhee, regenerative medicine researcher and founder of RheeGen®, a patent-pending topical regenerative platform, announced that his latest research abstract has been accepted for presentation at the 2026 Annual Meeting of the American Society of Interventional Pain Physicians (ASIPP)—one of the leading national conferences dedicated to interventional pain management, regenerative medicine, and emerging therapies for musculoskeletal conditions.
The ASIPP Annual Meeting 2026, scheduled for March 19–21, 2026 in New Orleans, will bring together physicians, researchers, and medical innovators from across the United States to present emerging clinical research, novel technologies, and new therapeutic approaches aimed at improving patient outcomes in pain medicine.
Dr. Rhee is a regenerative medicine researcher and innovator focused on non-invasive biological signaling technologies. As the creator of RheeGen®, a patent-pending topical regenerative platform designed to deliver advanced regenerative signaling through the skin, his research explores how cell-free biological signaling pathways may influence tissue recovery and support the development of next-generation non-invasive regenerative therapies.
Dr. Rhee’s accepted abstract focuses on cell-free regenerative signaling and advanced transdermal delivery systems, a growing area of interest within regenerative medicine that explores how biological signaling molecules can influence tissue repair without the need for live stem cell injections.
Interest in cell-free regenerative medicine has increased significantly in recent years as scientists and clinicians investigate how exosomes, growth factors, and other signaling molecules may activate the body’s natural repair mechanisms. These approaches aim to reduce procedural risk while offering new pathways for treating chronic musculoskeletal conditions, sports injuries, and degenerative joint disorders.
“The future of regenerative medicine is shifting toward non-invasive technologies that harness biological signaling to activate the body’s own repair mechanisms,” said Dr. Rhee. “By understanding how cellular communication influences healing, we can begin developing therapies that support recovery without relying solely on invasive procedures.”
Dr. Rhee has spent years researching regenerative medicine applications within musculoskeletal care. His work focuses on identifying ways that topical delivery platforms and biological signaling technologies may complement existing treatment options used in pain management and rehabilitation medicine.
The American Society of Interventional Pain Physicians Annual Meeting serves as an important forum for presenting new research findings and fostering collaboration among physicians, scientists, and innovators working at the forefront of pain medicine and regenerative science.
Dr. Rhee’s presentation will contribute to ongoing discussions about the future of regenerative therapies and the evolving role of cell-free signaling technologies in clinical medicine.
Media Contact
Company Name: At Large PR
Contact Person: Melinda Copeland
Email: Send Email
Country: United States
Website: www.atlargepr.com
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Dr. Tommy Rhee’s Research Accepted for Presentation at the 2026 ASIPP Annual Meeting
Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]
